Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AVTX
AVTX logo

AVTX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Avalo Therapeutics Inc (AVTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
15.400
1 Day change
7.47%
52 Week Range
24.270
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Avalo Therapeutics is not a clean buy right now for a Beginner long-term investor, even though the story is fundamentally interesting and analysts are broadly bullish. The stock has already moved sharply on positive LOTUS trial data, the technical trend is still bearish, and insider selling is a meaningful caution. For an impatient investor wanting to enter now rather than wait, I would not buy this at the current setup. My direct view is HOLD, not BUY.

Technical Analysis

AVTX is closed at 13.60, slightly below the prior close of 13.67. Momentum is mixed to weak: MACD histogram is -0.309 and still below zero, RSI_6 is 41.5, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. That structure suggests the longer trend has not fully reversed yet. Support is near 12.775, with resistance at 14.261 and then 15.747. The stock is sitting below pivot resistance, so the chart does not currently confirm a strong long entry, especially for a beginner investor seeking long-term exposure.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Options sentiment is moderately bullish on positioning but mixed on near-term trading flow. The put-call open interest ratio of 0.62 leans bullish, showing more call positioning than puts. However, the option volume put-call ratio of 2.0 means put volume was heavier than call volume in the most recent session, which signals some short-term hedging or bearish trading activity. IV is elevated at 122.17%, so the market is pricing in large expected moves, typical for a biotech name around catalyst-driven events. Overall, options suggest speculative interest remains high, but not a clean bullish confirmation.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
6

Positive Catalysts

  • Positive Phase 2 LOTUS data for abdakibart in hidradenitis suppurativa remains the main catalyst. Analysts broadly view the results as competitive and supportive of registrational development. Multiple firms raised price targets after the readout, including Piper Sandler, BTIG, Citizens, Mizuho, Wedbush, and H.C. Wainwright, which shows improving institutional confidence. Hedge funds are buying strongly, with buying up 829.12% over the last quarter.

Neutral/Negative Catalysts

  • There has been no news in the recent week, so near-term catalyst flow is quiet after the large trial-driven move. Insider activity is unfavorable, with insiders selling and the selling amount up 727.94% over the last month. Technically, the stock is still under a bearish moving-average structure. Options volume also leaned toward puts on the day, suggesting some defensive positioning. The stock has already re-rated sharply, so upside may be more dependent on future clinical/regulatory execution.

Financial Performance

No usable financial snapshot was provided, so latest-quarter revenue and earnings trends cannot be assessed here. For a clinical-stage biotech like AVTX, the investment case is driven more by trial execution and pipeline readouts than near-term operating fundamentals.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Wall Street sentiment is strongly positive overall. Recent rating changes were overwhelmingly bullish: Mizuho raised its target to $45 and kept Outperform, Wedbush lowered its target to $34 but kept Outperform, H.C. Wainwright lowered to $35 and kept Buy, Citizens lowered to $55 and kept Outperform, Piper Sandler raised to $60 and kept Overweight, and BTIG raised to $58 and kept Buy. The pros view is that LOTUS meaningfully de-risks abdakibart and supports registrational advancement. The con view is that some firms noted the data did not fully dominate competitive comparators, and the stock has already had a large run. Overall Wall Street is bullish, but the current entry is less attractive after the rally.

Wall Street analysts forecast AVTX stock price to rise
5 Analyst Rating
Wall Street analysts forecast AVTX stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.400
sliders
Low
25
Averages
40.4
High
50
Current: 15.400
sliders
Low
25
Averages
40.4
High
50
BofA
Buy
initiated
$35
AI Analysis
2026-06-12
Reason
BofA
Price Target
$35
AI Analysis
2026-06-12
initiated
Buy
Reason
BofA initiated coverage of Avalo Therapeutics with a Buy rating and $35 price target. The firm sees Avalo as a "cleaner, single-asset immunology story" after the positive Phase 2 data in hidradenitis suppurativa. The company's lead drug abdakibart could offer more convenient monthly dosing and superior disease impact versus competing drugs, the analyst tells investors in a research note.
Mizuho
NULL
to
Outperform
maintain
$39 -> $45
2026-05-14
Reason
Mizuho
Price Target
$39 -> $45
2026-05-14
maintain
NULL
to
Outperform
Reason
Mizuho raised the firm's price target on Avalo Therapeutics to $45 from $39 and keeps an Outperform rating on the shares post the Q1 report. The company continues to guide toward advancing abdakibart in hidradenitis suppurativa into registrational development, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AVTX
Unlock Now

People Also Watch